Universe's 15min chart shows KDJ Death Cross, bearish Marubozu pattern detected.
ByAinvest
Monday, Oct 13, 2025 12:37 pm ET1min read
GLTO--
Galecto Inc., focused on developing small-molecule drugs targeting fibrosis and cancer, saw the largest increase in momentum this week, rising from a score of 9.3 on Oct. 1 to 96.64. The stock is trading far above its 50-day moving average of $3.77 at $15.70 [1].
Xenetic Biosciences Inc., which develops cancer treatments that help the immune system fight tumors, saw a momentum gain of 75.56 points, rising from 21.97 to 97.53. The stock is also trading above its 50-day moving average of $3.23 at $9.70 [1].
Universe Pharmaceuticals Inc. went from a score of 12.95 to 82.24, trading above its 50-day moving average of $4.02 at $6.40, and is up more than 50% over the past month [1].
Alaunos Therapeutics, Inc., which develops cell therapies that use a patient's own immune cells to fight cancer, gained 68.77 points since last week, rising from 15.88 to 84.65. The stock is trading above its 50-day moving average of $2.43 at $3.95 and has gained more than 60% over the past month [1].
However, Universe Pharmaceuticals Inc. faces bearish signals according to the 15-minute chart. A KDJ Death Cross and a Bearish Marubozu at 10/13/2025 12:30 indicate a shift in momentum towards the downside, with a potential for further price decreases. Sellers are currently in control of the market, and it is likely that bearish momentum will continue .
TCRT--
UPC--
XBIO--
According to the 15-minute chart, Universe has triggered a KDJ Death Cross and a Bearish Marubozu at 10/13/2025 12:30. This indicates a shift in momentum towards the downside, with a potential for further price decreases. Sellers are currently in control of the market, and it is likely that bearish momentum will continue.
Healthcare and biotech stocks have been lagging behind broader markets this year, but a growing number of names have shown significant momentum. According to Benzinga's Edge Stock Rankings system, four biotech stocks have posted sharp increases in bullish momentum over the past week. These stocks are Galecto Inc. (NASDAQ:GLTO), Xenetic Biosciences Inc. (NASDAQ:XBIO), Universe Pharmaceuticals Inc. (NASDAQ:UPC), and Alaunos Therapeutics, Inc. (NASDAQ:TCRT).Galecto Inc., focused on developing small-molecule drugs targeting fibrosis and cancer, saw the largest increase in momentum this week, rising from a score of 9.3 on Oct. 1 to 96.64. The stock is trading far above its 50-day moving average of $3.77 at $15.70 [1].
Xenetic Biosciences Inc., which develops cancer treatments that help the immune system fight tumors, saw a momentum gain of 75.56 points, rising from 21.97 to 97.53. The stock is also trading above its 50-day moving average of $3.23 at $9.70 [1].
Universe Pharmaceuticals Inc. went from a score of 12.95 to 82.24, trading above its 50-day moving average of $4.02 at $6.40, and is up more than 50% over the past month [1].
Alaunos Therapeutics, Inc., which develops cell therapies that use a patient's own immune cells to fight cancer, gained 68.77 points since last week, rising from 15.88 to 84.65. The stock is trading above its 50-day moving average of $2.43 at $3.95 and has gained more than 60% over the past month [1].
However, Universe Pharmaceuticals Inc. faces bearish signals according to the 15-minute chart. A KDJ Death Cross and a Bearish Marubozu at 10/13/2025 12:30 indicate a shift in momentum towards the downside, with a potential for further price decreases. Sellers are currently in control of the market, and it is likely that bearish momentum will continue .
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet